Project Grant R21AI187752
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$428K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $427,625 to the University of North Carolina at Chapel Hill to investigate the role of Klebsiella pneumoniae fimbriae in liver abscess formation. The project aims to elucidate how the type 1 and type 3 fimbriae, which are surface-expressed protein appendages, contribute to the pathogenesis of...
The federal Project Grant award R21AI190454 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Illinois. The $456,911 award, effective July 1, 2025 through June 30, 2027, supports research to develop innovative antibiotic combination therapies for treating hypervirulent, multidrug-resistant Klebsiella pneumoniae infections. Key objectives include elucidating the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research provides $259,461 to The Methodist Hospital Research Institute to investigate the genomic factors and clinical impact associated with non-carbapenemase producing carbapenem-resistant Klebsiella pneumoniae (NCP-KPN) infections. The key objectives are to characterize a large international collection of NCP-KPN isolates using whole genome...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $249,000.00 to the Regents of the University of Minnesota to define the mechanisms by which macrophages restrict the bacterium Klebsiella pneumoniae (KP) during bloodstream infections (bacteremia). The research aims to 1) understand how splenic macrophages restrict KP during bacteremia, 2) elucidate host pathways of KP...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $521,030.00 to the University of North Carolina at Chapel Hill to conduct research on the role of phenotypic heterogeneity in the fitness of Clostridioides difficile, a leading cause of antibiotic-associated disease. The goal is to define the interplay between stochastic and regulatory mechanisms underlying the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $222,852 to support research into the regulation of virulence factors in the pathogenic bacterium Clostridioides difficile. The primary objective is to identify and annotate Rho, NusA, and NusG dependent transcriptional terminators in C. difficile to understand how these regulatory factors influence the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $189,558 to Duke University to identify genomic determinants of antibiotic treatment failure in Staphylococcus aureus bacteremia (SAB). The primary objectives are to: 1) Use a murine in-vivo evolution model to identify bacterial genotypes associated with SAB treatment failure, and 2) Conduct a genome-wide...
This federal Project Grant award of $254,478 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify mechanisms of resistance to pathogen-specific antibacterial antisense compounds and develop strategies to overcome them. The award recipient, The University of Texas Southwestern Medical Center, will investigate resistance to these novel antibacterial compounds called...
This federal Project Grant award of $169,811, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research conducted by the University of North Carolina at Chapel Hill (UNC-CH) to develop and apply innovative statistical methods for estimating the overall and spillover effects of infectious disease prevention interventions. The primary goal is to acquire training in infectious disease...
This Project Grant award of $747,763 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the development of small molecule inhibitors of the LPXH enzyme as novel antibiotics to treat multidrug-resistant Enterobacterales infections. The goal is to design and synthesize potent LPXH inhibitors with optimal drug-like properties, and demonstrate the safety and efficacy of a lead LPXH inhibitor candidate in a murine sepsis...